Skip to main content
NewslettersWatchlist

Abvc Biopharma Inc(ABVC-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.9020
Day High1.0200
Open:1.0000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Newswire.ca
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
BayStreet.ca
Biotech Innovations Drive Hope in Global Fight Against Pancreatic Cancer
TheNewswire.com
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
TheNewswire.com
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
TheNewswire.com
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
TheNewswire.com
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
TheNewswire.com
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
TheNewswire.com
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
TheNewswire.com
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
TheNewswire.com
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
TheNewswire.com
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
TheNewswire.com
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
Spotlight Growth
ABVC Biopharma (NASDAQ: ABVC) Inks Major Licensing Agreement with Xinnovation Therapeutics for ABV-1504 and ABV-1505
AllPennyStocks.com
Biotech Stock Soars On Strategic Investment Announcement
PR Newswire
ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand
PR Newswire
ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare
Globe Newswire
ABVC BioPharma Provides Vitargus® Update
Globe Newswire
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028
Globe Newswire
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update
Globe Newswire
Zacks Places Share Value of ABVC BioPharma at $9.50
Globe Newswire
ABVC BioPharma Provides Vitargus® Update
Globe Newswire
ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation
Globe Newswire
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
Globe Newswire
ABVC BioPharma Announces Termination of Two Contracts
Globe Newswire
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study
Globe Newswire
ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners
Globe Newswire
Prestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression Medicines
Globe Newswire
ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results
Globe Newswire
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding
Globe Newswire
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
Globe Newswire
ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process
Globe Newswire
ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed

Profile

ABCV BIOPHARMA identifies & commercializes drugs & medical devices developed. ABCV BIOPHARMA, formerly known as AMER BRIVISION, is based in FREMONT, CA.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.